Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + trastuzumab + oxaliplatin + capecitabine
- Development stage
- Unknown
- Lead developer
- Jiangsu Hengrui Medicine
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of camrelizumab (SHR-1210), trastuzumab, oxaliplatin, and capecitabine. Camrelizumab is a humanized anti-PD-1 monoclonal antibody that blocks PD-1 from binding to PD-L1, activating T-cells to attack cancer cells. Trastuzumab is a humanized monoclonal antibody targeting HER2 protein. Oxaliplatin is a platinum-based chemotherapy that forms platinum-DNA adducts inhibiting DNA replication. Capecitabine is an oral fluoropyrimidine chemotherapy converted to 5-fluorouracil in tumor tissues.
- Brand names
- AiRuiKaHerceptinXeloda
- Other names
- Camrelizumab + Trastuzumab + CAPOXCamrelizumab + Trastuzumab + XELOXSHR-1210 + Trastuzumab + Oxaliplatin + Capecitabine
02
Targets
TS (Thymidylate synthase)DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on camrelizumab + trastuzumab + oxaliplatin + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + trastuzumab + oxaliplatin + capecitabine.